Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I "expected" John to file the financials for NEWC for two years. For two years he promised the filing was just a week or two away, no problem, yadda yadda yadda. All lies as it turns out.
But this is different.
sure.
Opti
Extended hours
$6.40+0.04 (+0.63%)
Bid x Size
$6.39 x 100
Ask x Size
$6.40 x 700
August 2020 personal email from J Campo
Been meaning to get back to you. Last I left off with Christy Albeck, https://albeck.com/ , she wanted $ 10K for 2019. That's high, so I didn't push b/c I was looking at option to roll into VSYM. Either way we need to file a registration statement. I'm reaching out to Christy tonight to renegotiate with her with us doing the derivative valuations, which is really the hardest work besides consolidating. My goal is to get a stock trading again in conjunction with mining operations and benefit from Sannabis. To that end, the CAR opened up this week and our farm hand is going into town tomorrow to get copies of these notices, specifically the May 29- Informe Tecnico-Permisivo. https://sae.car.gov.co/modulos/saepublico/Expediente.aspx?ID=46825
Please reach out to me by Friday if you don't hear from me tomorrow on CAR.
Thanks,
John
John Campo
President
New Colombia Resources, Inc. & Sannabis Inc.
(1)-410-236-8200 USA (WhatsApp)
(57) 318-657-0918 Colombia
jcampo@newcolombiaresources.com
On its conference call, CEO Egan said that it continues to test clinical trials early in the fourth quarter. Given the urgent need for good testing, expect the U.S. and the European Union to approve the platform sooner than markets expect.
https://seekingalpha.com/article/4450537-why-co-diagnostics-is-a-solid-covid-19-play?mail_subject=codx-why-co-diagnostics-is-a-solid-covid-19-play&utm_campaign=rta-stock-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha
Opti
I considered John a friend. He emailed me weekly with updates. But he never delivered. And I ended up losing $47,000. Apparently this didn't bother him one bit. All he had to do was complete the financials and re-list the stock. I figure if the venture were real he would have followed thru. Only reason for not is that it all is one big scam.
He worked me and many others and then simply walked away.
Opti
See if this at all looks familiar:
Albeck Accounting is finishing up 2018 with Sadler Gibb auditor. I can bust out 2019 easy with other accountant and auditor one they give me 2018. Having 2 year audit make re-listing shares easier. I should have more concrete resolution in coming weeks.
I believe we're on last leg of waiting for CAR license, https://sae.car.gov.co/modulos/saepublico/Expediente.aspx?ID=46825
Our file is at legal department, we understand it's being approved, since they issued a technical report and didn't come back to us with comments. I'll keep you posted as soon as things are finalized and finally moving in right direction.
Enjoy your trip.
Regards,
John
John Campo
President
New Colombia Resources, Inc. & Sannabis Inc.
(1)-410-236-8200 USA (WhatsApp)
(57) 318-657-0918 Colombia
jcampo@newcolombiaresources.com
With NEWC John applied to the Colombian EPA for a coal-mining permit. He prepared an environmental impact statement. I know this because I contacted the agency and obtained copies of the permit application and other documents. The problem is the permit was never obtained. John blamed this on the agency, but he never met their requirements. It costs money to run a good scam. John will file permit applications and write letters to agencies, but he will not complete financials necessary for the stock. I assume that is because the financials will reveal the scam. Once the stock is de-listed, John will move on to his next scam and you will be left with no chance to get your money back.
I know this because I contacted the auditors and the lawyers and they all responded with disclaimers.
I have a ton of records backing all this up need a good class-action law firm.
Opti
Not really. In fact, I would double down on this and claim the entire stock market is a sham. Earnings make no difference in valuation; naked shorting is common, and hedge funds run the market. INO can indeed be a total sham company and it matters not to the stock market. The only thing that matters is who is running the market and how do you know what stocks are chosen to succeed.
People can make money on INO just as they can make or lose money on any other stock.
Opti
Consolidated Last Sale $11.04 +1.37 (+14.17%)
After-Hours Volume 713,272
After-Hours High $11.7 (04:07:11 PM)
After-Hours Low $9.67 (04:00:03 PM)
I have dozens of similar emails from John promising that the financials were close to completion and re-filing for re-listing was in the very near future. For two years he promised me he was going to bring NEWC back to life.
He is a pathological liar.
Opti
Co-Diagnostics EPS beats by $0.11, beats on revenue
Aug. 12, 2021 4:03 PM ET Co-Diagnostics, Inc. (CODX)
By: Manshi Mamtora, CFA3 Comments
Co-Diagnostics (NASDAQ:CODX): Q2 GAAP EPS of $0.33 beats by $0.11.
Revenue of $27.4M (+14.0% Y/Y) beats by $6.63M.
Press Release
Q3 Outlook: Revenue to be in the range of $23.0 million to $25.0 million
Diluted earnings per share forecasted to be in the $0.19 to $0.22 range.
Opti
copied below is a 2017 email from John Campo. None of what he promised came to be. None of it. The stock is de-listed.
The auditors should have Q2-3 done soon, I'm getting update from them tomorrow. I really think they'll be out by next friday, and subsequently the 10K and Q's and K for 2016. Once the first filing hits I will give confidence to investors.
The auditors have been paid, the accountants have been paid, all documentation has been submitted, all disclosures are current, therefore, I do not foresee any further delays in the filings.
I've been working on deals that will bring in revenue and interest to the company, but we need exposure which is forthcoming. I want to get a filing out so these events are credible, in the meantime, I'm setting up for a nice summer.
Sannabis is special because we're helping people live better, their testimonies is what drives us, go figure all from a plant that been around for thousands of years. There are things about Sannabis I have to keep quiet to maintain our small producer status here in Colombia. When the regulations are resolved we will apply for our licenses as a small producer so that we don't get a big application fee. We'll have non-THC product legally selling in the U.S. soon.
The press will begin once first filing hits.
That's a fact.
Opti
thank you for your response.
a kind word.
Opti
NEWC had auditors, accountants, lawyers, etc. Simply a stall and shell game. The end will be delisting and total loss of investment.
Let it play out and call me back in a year.
Opti
good first step of DD is to check a company's website. Keep your insults to your family.
Opti
Check out the web page. Some sections have not been updated for 4 years. That alone is troubling.
Opti
Trust us, this will not end well.
Opti
Envirotech Vehicles nabs stockholder approval for reverse stock split for Nasdaq uplisting
Aug. 10, 2021 7:28 AM ETADOMANI, Inc. (ADOM)By: Khyathi Dalal, SA News Editor
Envirotech Vehicles' (OTCQB:ADOM) stockholders approved by an 85.8% to 14.2% margin an amendment to the company's Amended and Restated Certificate of Incorporation to implement a reverse stock split of the outstanding shares of common stock, within a range from 1-for-4 to 1-for-20.
The exact ratio will be determined by the board.
It expects to file an application to list its common stock on Nasdaq and would effect the reverse split for meeting the exchange minimum trading price requirement.
Opti
Inovio Pharmaceuticals EPS misses by $0.14, misses on revenue
Aug. 09, 2021 4:07 PM ETInovio Pharmaceuticals, Inc. (INO)By: Gaurav Batavia, SA News Editor
Inovio Pharmaceuticals (NASDAQ:INO): Q2 GAAP EPS of -$0.39 misses by $0.14.
Revenue of $0.27M (flat Y/Y) misses by $0.94M.
Shares -1.5%.
Press Release
As of June 30, 2021, cash and cash equivalents and short-term investments were $443.7 million compared to $411.6 million as of December 31, 2020.
Opti
Quote: CEO Tweet: “ 17h “The ship does not sink.
We are moving the chips to keep up with the financial statements. Also to remove the CE, expect more updates soon.”
--------------------------
I have a hundred similar promises from Campo regarding NEWC. It was always "expect good news next week".
Mr Campo is a pathological liar
Opti
Nothing owning Nothing. Sweet.
Opti
Opti, you believe this one will have the same fate as NEWC?
Yes, I do.
Opti
The next report will be the delighting. Same as NEWC.
Opti
I would advise holding. Masks are not in demand right now and that is a big part of their business.
Opti
From today's filing: Recent Developments
Because we believe that testing for the COVID-19 virus is going to be a consideration for public health worldwide even after the current pandemic has subsided, we have initiated a project to facilitate frequent testing in schools, businesses, and the hospitality industry. We believe this may be accomplished through the development of a low cost, easy to use by non-professionals, testing device that can provide PCR quality test results in less than an hour. This project is possible due to the facts that in 2020 we were able to successfully lyophilize our Logix Smart Covid-19 test reagents and additionally developed a saliva-based collection system that does not require the RNA/DNA extraction. While the final result is the same as if done through a lab-based IVD process, it has the advantages of increased speed and ease of handling thanks to lyophilization. We have engaged the services of a group of professionals who have the expertise to develop the hardware for such a device using our CoPrimers as the reagent chemistry. The device will be available to homes, offices, event facilities, and the travel industry at a cost that will allow screening frequently to prevent spread of the COVID-19 virus in the future. The device would also be available to test for other pathogens detectable through saliva samples as we develop those tests and offer them to the marketplace.
12:30 pmCo-Diagnostics New Eikon Platform Provides PCR Results for At Home and Point of Care Testing
Dwight Egan, CEO, Co-Diagnostics, Inc
The Eikon platform, is designed to complete all necessary steps in a “sample to result” process. The user, whether at home, school, or work will be able to “walk away” while the system provides rapid results through the app in less than 30 minutes. In this presentation, Co-Diagnostics’ CEO Dwight Egan will introduce the Eikon platform along with Masen Christensen, Senior Design Engineer, who will describe the underlying CoPrimer technology.
Co-Diagnostics, Inc. to Present at Upcoming Technology and Health Research Conferences
SALT LAKE CITY, June 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting virtually this week at the 28th International Biodetection Technologies Conference as well as hosting a virtual booth at the 65th Annual CARPHA Health Research Conference.
The Biodetection Technologies Conference, an internationally recognized meeting for experts in detection and identification of biological threats held on June 18, will focus on point-of-care diagnostics for improving global health and biodefence. Co-Diagnostics' presentation at 12:30 pm ET will include a discussion of its point-of-care and at-home rapid PCR diagnostics platform currently in development, as the platform relates to supporting sample-to-result COVID-19 testing initiatives at the places where interactions take place to help normalize work, school, home and travel routines. The presentation will also provide insight into aspects of the underlying CoPrimer™ technology and the results of the Company's analysis relative to global strains and variants of SARS-CoV-2.
The theme for the 2021 virtual Caribbean Public Health Agency (CARPHA) Health Research Conference, held June 16-19, 2021, is "Pandemic, NCDs and Climate Change: The Caribbean's Triple Threat." According to the conference website, NCDs, or non-communicable diseases, are the leading cause of death in the Caribbean region, which has also been greatly impacted by the effects of the COVID-19 pandemic. The Company has been attending the CARPHA conference since 2017, and its virtual booth will present Co-Diagnostics' infectious disease and vector control products to conference attendees.
To learn more about the two conferences, including registration details, please visit biodetectiontechnologies.com/point-of-care-diagnostics and carphaconference.vfairs.com. An archived version of the Biodetection Technologies presentation can be accessed on the Events and Webcasts section of the Co-Diagnostics website following the conclusion of the conference.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
SOURCE Co-Diagnostics
Reddit favorite Inovio Pharmaceuticals takes a breather; down 9%
Jun. 10, 2021 11:27 AM ETInovio Pharmaceuticals, Inc. (INO)By: Jonathan M Block, SA News Editor8 Comments
Shares of Inovio Pharmaceuticals (NASDAQ:INO), one of several biotech stocks recently talked up on Reddit forum, are down 9.4% in morning trading.
However, shares are still up 7.9% over the last 5 trading days.
Like several other biotechs hot on Reddit, Inovio has few buy ratings from analysts and has more than a quarter of its float on loan.
The Wall Street Journal research ratings on Inovio show that among nine analysts, six view the stock as a hold, while three see it as a buy.
Inovio's latest stage asset is VGX-3100 for diseases associated for human papillomavirus.
In phase 2, it has MEDI0457 in partnership with AstraZeneca for various cancers.
Inovio also has INO-5401 in phase 2 with Regeneron for glioblastoma multiforme.
Opti
Co-Diagnostics Stock Set To Create Shareholder Value (CODX) | Seeking Alpha
Co-Diagnostics: No One-Hit Wonder
Jun. 04, 2021 4:22 PM ET Co-Diagnostics, Inc. (CODX)3 Comments1 Like
Summary
• Vaccine hesitancy and new coronavirus variants are a threat to herd immunity. The alternative solution to vaccination for re-opening the economy is mass testing.
• Co-Diagnostics is expected to benefit from higher COVID-19 testing demand as travel resumes.
• A fortress-like balance sheet makes CODX ideally positioned to invest for growth and to create shareholder value.
• A high valuation and uncertainty around government policy toward COVID-19 testing is a material risk to the stock price.
Conclusion
• CODX is expected to benefit from a re-opening economy. As travel resumes, the demand for COVID-19 tests will support revenue growth at CODX. Vaccinations alone won't be able to combat the pandemic and new coronavirus variants effectively. The solution to this problem is testing. CODX is in great financial shape and has sufficient financial resources to invest for growth and create shareholder value. However, a high valuation and government policy uncertainty are significant risks to the stock price.
Hopefully jail is next.
Opti
New rules will affect your ability to buy and sell “Pink No Information” securities, including at E*TRADE
On September 28, 2021, new requirements take effect that will impact the market for—and value of—certain “over-the-counter (OTC) securities” you currently hold or have held in the past. The new rules apply to “Pink No Information” OTC securities of companies that fail to publicly report and keep current financial and other company information and will restrict the ability of U.S. brokers, like E*TRADE from making these products generally available.
Some background on the new requirements
The Securities and Exchange Commission (SEC) recently adopted amendments to SEC Rule 15c2-11 governing the submission and publication of OTC quotations. These amendments will prohibit broker-dealers from submitting or publicly disseminating bid/ask quotations for OTC securities of issuers that do not meet enhanced information filing requirements.
Securities of issuers that make the required information publicly available by the deadline in the rule should not be affected.
What these changes mean for you
Starting September 28, 2021, you will no longer be able to buy or sell “Pink No Information” OTC securities through E*TRADE
Co-Diagnostics EPS beats by $0.04, beats on revenue
May 13, 2021 4:11 PM ETCo-Diagnostics, Inc. (CODX)By: Gaurav Batavia, SA News Editor
Co-Diagnostics (NASDAQ:CODX): Q1 GAAP EPS of $0.26 beats by $0.04.
Revenue of $20M beats by $0.11M.
Gross profit increased to $16.8 million, representing 83.7% of consolidated revenue due to improved product mix as compared to the prior-year period.
Shares +5%.
Co-Diagnostics, Inc. $8.14
Co-Diagnostics, Inc. (CODX) is confirmed to report earnings at approximately 4:00 PM ET on Thursday, May 13, 2021. The consensus earnings estimate is $0.20 per share on revenue of $19.50 million. Investor sentiment going into the company's earnings release has 71% expecting an earnings beat. Consensus estimates are for year-over-year earnings growth of 500.00% with revenue increasing by 1,158.88%. Short interest has increased by 3.9% since the company's last earnings release while the stock has drifted lower by 26.7% from its open following the earnings release to be 38.6% below its 200 day moving average of $13.27. Option traders are pricing in a 16.9% move on earnings and the stock has averaged a 14.6% move in recent quarters.
APT up 10% on earnings--missed on earnings but beat on revenue. When CODX did this we tanked, but APT soars. Maybe we can expect gains next Thursday. Note APT and CODX seem to travel in pairs and have tracked pretty evenly for the past year. I see the APT movement as a good sign.
Opti
APT up 10% on earnings--missed on earnings but beat on revenue. When CODX did this we tanked, but APT soars. Maybe we can expect gains next Thursday. Note APT and CODX seem to travel in pairs and have tracked pretty evenly for the past year. I see the APT movement as a good sign.
Opti
Record revenue and profits and near 52 week low pps. Makes total sense.